EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis

Anat Tsur iD, Avivit Cahn iD, Lior Hanoch, Rena Pollack

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Anat Tsur und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Clalit Health Services, Jerusalem, Israel. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Insulin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim Diabetic kidney disease (DKD) is a major complication of diabetes, including in insulin‐deficient phenotypes, yet data on kidney outcomes with sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in this population are limited. This study investigates the impact of SGLT2i on kidney outcomes in patients with insulin‐deficient diabetes using real world data. Materials and Methods This retrospective cohort study utilized data from a large Health Maintenance Organization in Israel and included 12,530 propensity score‐matched adults with insulin‐deficient diabetes. Patients were categorized into SGLT2i users and non‐users and followed for a median of 1657 days. The primary outcome was a composite of ≥50% decline in eGFR to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetic NephropathiesDiabetes Mellitus, Type 2InsulinHumansMaleFemaleMiddle AgedRetrospective StudiesAgedIsraelPhenotypeGlomerular Filtration RateKidneyAdultTreatment OutcomeAlbuminuria

Stichwörter der Autor:innen

SGLT2 inhibitordiabetic nephropathyreal‐world evidencetype 1 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsInsulin

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Clalit Health Services, Jerusalem, Israel.
  • The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel.

ORCID-Profile: Anat Tsur, Avivit Cahn

Zitieren

APA

Tsur, A., Cahn, A., Hanoch, L., & Pollack, R. (2025). Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16329

Vancouver

Tsur A, Cahn A, Hanoch L, Pollack R. Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16329

BibTeX
@article{Tsur2025,
  author = {Tsur, Anat and Cahn, Avivit and Hanoch, Lior and Pollack, Rena},
  title = {Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16329}
}
Kostenlos starten →